DNMT3A-mediated DNA methylation and transcription inhibition of FZD5 suppresses lung carcinogenesis

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Non-small cell lung cancer (NSCLC) is a major health concern.
• Aberrant gene expression plays a critical role in NSCLC pathogenesis.
• Frizzled 5 (FZD5) has been identified as a potential factor in NSCLC development.

Purpose of the Study:

• To investigate the correlation between Frizzled 5 (FZD5) expression and non-small cell lung cancer (NSCLC).
• To elucidate the role of FZD5 in NSCLC tumorigenesis and malignant behavior.
• To explore the epigenetic regulation of FZD5 in NSCLC.

Main Methods:

• Established a mouse model for primary NSCLC using urethane injection.
• Utilized lentivirus-mediated FZD5 silencing in vivo and in vitro.
• Assessed DNA methylation levels using quantitative methylation-specific PCR.
• Investigated DNA methyltransferases (DNMTs) binding to the FZD5 promoter via chromatin immunoprecipitation.
• Overexpressed DNMT3A in mice and NSCLC cells to confirm its regulatory role.

Main Results:

• Elevated FZD5 expression was observed in NSCLC.
• FZD5 knockdown reduced tumor incidence in mice and inhibited proliferation, migration, and invasion of NSCLC cells in vitro.
• Reduced promoter methylation of FZD5 correlated with its aberrant upregulation in NSCLC.
• DNMT3A, a suppressor of FZD5 transcription, was underexpressed in NSCLC.
• DNMT3A upregulation suppressed lung carcinogenesis and malignant phenotypes in NSCLC.

Conclusions:

• Reduced DNA methylation-induced activation of FZD5 is linked to NSCLC onset and progression.
• DNMT3A acts as a tumor suppressor in NSCLC by downregulating FZD5.
• Targeting FZD5 and DNMT3A may offer therapeutic strategies for NSCLC.